This prevents tumor escape via the downregulation of MHC molecules [6,7] and confers CAR T cells with the ability to recognize non-peptide antigens such as glycolipids or tumor-specific glycosylation patterns [58,59]. This evidence concerns the gene HLA-C and neoplasm.